Form 4: Repare Therapeutics CEO Lloyd Segal Reports Stock and Option Transactions

CEO Lloyd Mitchell Segal reports acquisition of restricted stock units and stock options, along with indirect holdings through Arvala Inc.

Summary

• Repare Therapeutics' CEO, Lloyd Mitchell Segal, filed a Form 4 detailing changes in beneficial ownership.
• On March 1, 2024, Segal acquired 40,000 restricted stock units (RSUs) that vest in three equal installments on March 1, 2025, March 1, 2026, and March 1, 2027, contingent on continued service.
• Segal also acquired an option to purchase 237,000 common shares at an exercise price of $6.95, with 25% vesting on March 1, 2025, and the remainder vesting monthly thereafter over 36 months, also contingent on continued service.
• Segal indirectly owns 94,466 common shares through Arvala Inc., where he is the sole stockholder.
• The transactions were reported by Steve Forte, Attorney-in-Fact, on March 4, 2024.

Sentiment

Score: 6

Explanation: The document is a neutral regulatory filing. The granting of equity can be seen as a positive sign of alignment, but it's a routine event.

Positives

• The granting of RSUs and stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.
• The vesting schedules for both the RSUs and stock options encourage long-term commitment from the CEO.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent.
• Vesting schedules are typically structured to align executive incentives with long-term company performance, often over a 3-4 year period, which is consistent with the vesting schedule outlined in the document.
• Comparable companies such as Relay Therapeutics, Black Diamond Therapeutics, and Kinnate Biopharma also utilize stock options and RSUs as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign of management's commitment to the company's long-term success.
• Employees may be motivated by the fact that the CEO's incentives are aligned with the company's performance.

Key Dates